Gossamer Bio Inc (GOSS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.73 (-10.13%), Market cap $0.08B, 52-week low–high $0.32 ~ $3.79.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and i
Financial statements, price targets, institutional (13F) holdings and related news for Gossamer Bio Inc are updated in real time on BlackAll Trade.
Gossamer Bio Inc trades at $10.73 (-10.13%). Real-time quotes and charts are available on BlackAll Trade.
Gossamer Bio Inc has a market cap of about $0.08B.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in